DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

ClinicalTrials.gov ID: NCT04567420

Public ClinicalTrials.gov record NCT04567420. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 11:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Study identification

NCT ID: NCT04567420
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Criterium, Inc.; Industry
Enrollment: 70 participants

Conditions and interventions

Conditions

Breast Cancer

Interventions

Adjuvant Therapy Drug
Fulvestrant Drug
Palbociclib Drug

Drug

Eligibility (public fields only)

Age range: Not listed
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 8, 2021
Primary completion: Dec 30, 2027
Completion: Dec 30, 2028
Last update posted: Oct 15, 2025

2021 – 2028

United States locations

U.S. sites: 19
U.S. states: 16
U.S. cities: 18

Facility	City	State	ZIP	Site status
University of Arizona Cancer Center	Tucson	Arizona	85724	Recruiting
USC/Norris Comprehensive Cancer Center	Los Angeles	California	90033	Recruiting
Cedars-Sinai Medical Center	Los Angeles	California	90048	Completed
University of Colorado Cancer Center	Aurora	Colorado	80045	Recruiting
Intermountain	Golden	Colorado	80401	Recruiting
Yale Cancer Center	New Haven	Connecticut	06510	Recruiting
Winship Cancer Institute of Emory University	Atlanta	Georgia	30322	Recruiting
Louisiana State University Health Sciences Center- New Orleans	New Orleans	Louisiana	70112	Recruiting
Cancer Partners of Nebraska	Lincoln	Nebraska	68516	Recruiting
New Mexico Cancer Care Alliance	Albuquerque	New Mexico	87131	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
Stony Brook University Cancer Center	Stony Brook	New York	11794	Recruiting
The Ohio State University Wexner Medical Center James Cancer Hospital	Columbus	Ohio	43210	Recruiting
Stephenson Cancer Center	Oklahoma City	Oklahoma	73104	Recruiting
Oregon Health and Science University	Portland	Oregon	97239	Recruiting
PRiSMs Group	Laredo	Texas	78041	Recruiting
Virginia Cancer Institute	Richmond	Virginia	23229	Recruiting
Swedish Cancer Institute	Seattle	Washington	98104	Recruiting
University of Wisconsin Clinical Science Center	Madison	Wisconsin	53792	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04567420, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 15, 2025 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04567420 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →